GlassScriptPhysician profile
Alix Lanoue
NPI 1598766099
$4,786.24
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $273 · 2021: $202 · 2022: $1,171 · 2023: $1,376 · 2024: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,119.58 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.44 | 2019-2024 | Xifaxan, Plenvu |
| Celgene Corporation | $437.52 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $368.65 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Genzyme Corporation | $353.80 | 2022-2024 | |
| Qol Medical, LLC | $340.11 | 2021-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $302.21 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $195.15 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $185.06 | 2019-2024 | Ocaliva |
| Gilead Sciences, INC. | $181.49 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $108.85 | 2019-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $91.17 | 2019-2020 | |
| Shionogi INC | $61.63 | 2019 | |
| Lilly USA, LLC | $61.03 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $58.99 | 2022-2024 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $56.88 | 2021 | |
| Daiichi Sankyo INC. | $40.18 | 2019 | |
| Braintree Laboratories, INC. | $37.88 | 2020-2023 | Suflave |
| Ferring Pharmaceuticals INC. | $34.30 | 2019 | |
| Allergan, INC. | $33.83 | 2019 | |
| Pfizer INC. | $28.72 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $26.15 | 2023 | Bylvay |
| Glaxosmithkline, LLC. | $21.82 | 2022 | |
| Alfasigma USA, INC. | $21.40 | 2020 | |
| Ardelyx, INC. | $18.33 | 2023 | Ibsrela |
| Vivus LLC | $17.87 | 2024 | Qsymia |
| Amgen INC. | $17.65 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.33 | 2023 | Zeposia |
| Boston Scientific Corporation | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alix Lanoue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.